What Happens To BioSante Pharmaceuticals Now?

By Staff and Wire Reports

Friday, 20 April 2012 06:43

Last December, shares of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) imploded after the firm’s sexual dysfunction drug LibiGel failed in two late-stage clinical trials. Have we heard the end of that program? Probably not, actually.
Stephen M. Simes, BioSante’s president & CEO sat down for a revealing video interview with BioMedReports and explains, quite candidly, what happened and where his firm is headed now.

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now

“We continue to analyze those data and hope to come up with perhaps a different strategic way to attack the issue either to redo LibiGel clinical trials or to find another use for our safety data, “explains Simes. “I talked about our efficacy data so far, the safety data are quite remarkable. We’re now in the fifth year of the LibiGel testosterone safety study and we’re showing very clearly that testosterone is safe for women. So the question is how best to use those safety data, which is now the biggest database of safety of testosterone in women that’s ever existed.

“We expect to meet with the FDA and be able to announce the next steps for LibiGel, which is, still quite an interesting opportunity because today as you know there is no product approved for the treatment of female sexual dysfunction.”

Simes is expected to present a corporate update at the BioCentury Future Leaders in the Biotech Industry Conference in New York today at 11:00 am EDT. In the meantime, the revealing interview can be seen below.

Disclosure: None

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites

blog comments powered by Disqus

Newsletter